Mersana Therapeutics Inc

+0.05 (+1.45%)
Earnings Announcements

Mersana Therapeutics Q1 Loss Per Share $0.59

Published: 05/09/2022 13:46 GMT
Mersana Therapeutics Inc (MRSN) - Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results.
Q1 Loss per Share $0.59.
Mersana Therapeutics - Expects Available Funds to Be Sufficient to Support Its Operating Plan Commitments Well Into H2 of 2023 .
Further Company Coverage: .
Revenue is expected to be $1.61 Million
Adjusted EPS is expected to be -$0.53

Next Quarter Revenue Guidance is expected to be $1.61 Million
Next Quarter EPS Guidance is expected to be -$0.54

More details on our Analysts Page.